Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of CCDC130 autoantibody detection reagent in preparation of lung cancer screening kit

A CCDC130, autoantibody technology, applied in biological tests, measurement devices, material inspection products, etc., can solve the problem of no lung cancer, and achieve good application prospects, effective screening, and low patient harm.

Active Publication Date: 2019-11-15
WEST CHINA HOSPITAL SICHUAN UNIV +1
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are no relevant reports on CCDC130 protein autoantibodies, and there is no prior art related to lung cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of CCDC130 autoantibody detection reagent in preparation of lung cancer screening kit
  • Use of CCDC130 autoantibody detection reagent in preparation of lung cancer screening kit
  • Use of CCDC130 autoantibody detection reagent in preparation of lung cancer screening kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1 Relationship between CCDC130 Autoantibodies in Plasma and Lung Cancer

[0027] 1. Clinical data

[0028] Select 30 cases of lung cancer patients, 29 cases of benign lung diseases (tuberculosis, hamartoma and other non-malignant tumors), and 30 cases of healthy controls. The basic information is as follows:

[0029] Basic Information lung cancer patients benign lung disease healthy control number of people 30 29 30 age 58±10.5 46.5±10.0 42±8.9 male ratio 20(66.7) 12(41.4％) 13(46.7％)

[0030] 2. Detection principle

[0031] HuProt TM The CCDC130 protein is immobilized on the human protein custom chip. After incubation with serum, CCDC130 autoantibodies (mainly including IgG, IgM antibodies, and some other types of antibodies) in the serum will bind to it, and the unbound antibodies and other proteins will be removed by washing. Then use anti-human IgM fluorescently labeled secondary antibody (cy5-labeled, red) and a...

Embodiment 2

[0047] Embodiment 2 The composition of detection kit of the present invention and its application method

[0048] 1. Kit composition

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of in vitro diagnostic reagents, and in particular relates to use of a CCDC130 autoantibody detection reagent in preparation of a lung cancer screening kit. The factthat the autoantibody level of CCDC130 protein in the serum of a patient with lung cancer is obviously higher than that of a health patient is found in the invention for the first time. The reagent for detecting a CCDC130 protein autoantibody is used for preparing the lung cancer screening kit in the invention; and thus, effective lung cancer screening can be realized.

Description

technical field [0001] The invention relates to the field of in vitro diagnostic reagents, in particular to the use of CCDC130 autoantibody detection reagents in the preparation of lung cancer screening kits. Background technique [0002] Lung cancer is one of the most common malignant tumors in the world. Its morbidity and mortality are increasing year by year. Currently, the incidence rate ranks first in the world, which seriously threatens human health and life. [0003] Lung cancer is a disease that is good at concealment. It often shows clinical symptoms when the disease develops to an advanced stage. 70-80% of lung cancer patients are already in the middle or late stage when they are diagnosed with lung cancer symptoms. The best cure time, five-year survival rate is low. For patients with early lung cancer, timely treatment can greatly improve the 5-year survival rate and quality of life of the patients. Therefore, early diagnosis and effective screening of lung canc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68G01N33/574
CPCG01N33/6884G01N33/57423G01N33/57484
Inventor 李蕊岑唐怀蓉黄燕李文钰
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com